May 12, 2025
Rx Pricing’s Lucy & the Football Moment?
Investors should view today’s drug pricing Executive Order (EO) with relief, and while the biopharma industry remains on notice for potential future regulatory actions, we suspect the courts would intervene to stop any overly broad…